Exelixis

Source: seekingalpha.com --- 40 days ago
Ohad Hammer submits: The pharmaceutical industry is in the midst of a severe innovation crisis, where more R&D money results in less approved drugs. In parallel, sales of most traditional blockbusters are being cannibalized by generic competition, forcing the big pharmas to exploit new concepts and rush new drug candidates to their pipelines. Nearly half of all drugs that are expected to enter the clinic in the coming years will be aimed at the oncology market. Consequently, early stage drug development for cancer is going to be the most active area in the industry, with an abundance of investment opportunities, particularly in small and medium companies. Complete Story » ...

Source: www.genengnews.com --- 11 days ago
...

Source: www.ncbi.nlm.nih.gov --- 27 days ago
Related Articles Modeling spinal muscular atrophy in Drosophila. PLoS ONE. 2008;3(9):e3209 Authors: Chang HC, Dimlich DN, Yokokura T, Mukherjee A, Kankel MW, Sen A, Sridhar V, Fulga TA, Hart AC, Van Vactor D, Artavanis-Tsakonas S Spinal Muscular Atrophy (SMA), a recessive hereditary neurodegenerative disease in humans, has been linked to mutations in the survival motor neuron (SMN) gene. SMA patients display early onset lethality coupled with motor neuron loss and skeletal muscle atrophy. We used Drosophila, which encodes a single SMN ortholog, survival motor neuron (Smn), to model SMA, since reduction of Smn function leads to defects that mimic the SMA pathology in humans. Here we show that a normal neuromuscular junction (NMJ) structure depends on SMN expression and that SMN concentrates in the post-synaptic NMJ regions. We conducted a screen for genetic modifiers of an Smn phenotype using the Exelixis collection of transposon-induced mutations, which affects approximately 50% of the Drosophila genome. This screen resulted in the recovery of 27 modifiers, thereby expanding the genetic circuitry of Smn to include several genes not previously known to be associated with this locus. Among the identified modifiers was wishful thinking (wit), a type II BMP receptor, which was shown to alter the Smn NMJ phenotype. Further characterization of two additional members of the BMP signaling pathway, Mothers against dpp (Mad) and Daughters again ...

Source: www.moreover.com --- 85 days ago
The South San Francisco company (NASDAQ: EXEL) will test the drug, XL184, in some 315 patients in this Phase III trial. ...

Source: www.fool.com --- 82 days ago
Pivotal clinical trial results for a top drug are finally within sight. ...

Source: www.fool.com --- 104 days ago
Sometimes, even the best couples break up. ...

Source: sanjose.bizjournals.com --- 69 days ago
Exelixis Inc. on Tuesday reported a second quarter loss of $45.1 million, or 43 cents a share, compared to $28.6 million, or 29 cents a share for the same period last year. (EXEL) ...

Source: www.businesswire.com --- 69 days ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) today reported financial results for the second quarter ended June 30, 2008. ...

Source: www.businesswire.com --- 46 days ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--First graph, second sentence of release should read: Mr. Karbe will discuss updates to the company’s development ...

Source: www.cen-chemjobs.org --- 103 days ago
• BS/BA degree in chemistry, bioengineering or chemical engineering or related disciplines with 3 years of laboratory experience; or, • MS/MA degree in chemistry, bioengineering or chemical engineeri ...

Source: seekingalpha.com --- 69 days ago
Exelixis Inc. (EXEL) Q2 2008 Earnings Call Complete Story » ...

Source: www.centredaily.com --- 49 days ago
Exelixis, Inc. (Nasdaq:EXEL) announced today that Frank Karbe, Executive Vice President and Chief Financial Officer of Exelixis, will present at the Thomas Weisel Partners 2008 Healthcare Conference at 10:20 a.m. ET/7:20 a.m. PT on Wednesday, September 3, 2008. Mr. Karbe will discuss updates to the company's development pipeline and corporate strategy. ...

Source: www.ad-hoc-news.de --- 88 days ago
Exelixis Appoints Frances K. Heller As Executive Vice President of Business DevelopmentSOUTH SAN FRANCISCO, Calif.CA-Exelixis ...

Source: www.streetinsider.com --- 67 days ago
Visit StreetInsider.com at http://www.streetinsider.com/Upgrades/Friedman+Billings+Upgrades+Exelixis+%28EXLS%29+to+Market+Perform+/3892881.html for the full story. ...

Source: www.genengnews.com --- 78 days ago
...

Source: www.stockworld.de --- 69 days ago
...

Source: www.stockworld.de --- 60 days ago
...

Source: www.topix.com --- 67 days ago
Yesterday, Exelixis announced second-quarter earnings numbers -- yawn, another loss -- but, more importantly, also discussed its future in depth. ...

Source: www.canceraids.org --- 4 days ago
Exelixis, Inc. (Nasdaq:EXEL) announced today that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration for XL888, a novel anticancer compound. XL888 is an orally available small molecule inhibitor of HSP90, which is a chaperone protein that promotes the activity and stability of a range of key regulatory [...] ...

Source: www.topix.com --- 8 days ago
Main Category: Cancer / Oncology Also Included In: Regulatory Affairs / Drug Approvals Article Date: 05 Oct 2008 Exelixis, Inc. ...